Science Applications Stock Plunges 13% as Q1 Earnings Miss Estimates
Science Applications International Corporation price-consensus-eps-surprise-chart | Science Applications International Corporation Quote
Segment-wise, revenues from Defence and Intelligence, which accounted for 76.3% of revenues, amounted to $1.43 billion and decreased 0.2% year over year. Civilian revenues, which constitute 23.7% of revenues, totaled $444 million and rose 8% year over year.Net bookings for the quarter were approximately $2.4 billion, which reflected a book-to-bill ratio of 1.3. The company's trailing 12-month book-to-bill ratio was 0.8 at the end of the fiscal first quarter. SAIC's estimated backlog at the end of the quarter was approximately $22.3 billion. Of the total backlog amount, approximately $3.3 billion was funded.Selling, general and administrative (SG&A) expenses decreased 4.7% to $89 million. SG&A expenses, as a percentage of revenues, increased to 4.7% from 4.6% in the year-ago quarter.Non-GAAP operating income decreased year over year to $158 million from the year-ago quarter's operating income of $165 million. The non-GAAP operating margin contracted 50 basis points (bps) year over year to 8.4%. Adjusted EBITDA declined 5.42% to $157 million. Adjusted EBITDA margin for the quarter was 8.4% compared with 9% for the prior-year quarter. Margin performance was impacted by the typical seasonality of investments, including healthy submit volumes and higher costs on a fixed price program in the space business.
Science Applications ended the fiscal first quarter with cash and cash equivalents of $47 million, down from the previous quarter's $56 million.As of May 2, 2025, Science Applications' long-term debt (net of the current portion) was $1.876 billion compared with $1.907 billion as of Jan. 31, 2025.The company generated operating and used free cash flows of $100 million and $44 million, respectively, in the fiscal first quarter.During the fiscal first quarter, Science Applications repurchased shares worth $125 million and paid $19 million in dividends.
Science Applications reaffirms its fiscal 2026 revenues in the range of $7.60-$7.75 billion and adjusted earnings in the $9.10-$9.30 band. The Zacks Consensus Estimate for fiscal 2026 revenues and non-GAAP earnings is pegged at $7.67 billion and $9.19 per share, respectively. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)The company projects its adjusted EBITDA in the band of $715-$735 million and the adjusted EBITDA margin to be approximately 9.4-9.6%. SAIC expects its free cash flow to be in the band of $510-$530 million.
Currently, SAIC carries a Zacks Rank #3 (Hold).Paylocity Holding PCTY, StoneCo STNE and Trivago TRVG are some better-ranked stocks that investors can consider in the broader Zacks Computer & Technology sector.PCTY, STNE and TRVG sport a Zacks Rank #1 (Strong Buy) each at present. You can see the complete list of today's Zacks #1 Rank stocks here.PCTY shares have declined 4.5% year to date. The Zacks Consensus Estimate for PCTY's full-year 2025 earnings is pegged at $7.01 per share, up by 5.4% over the past 30 days, indicating an increase of 6.7% from the year-ago quarter's reported figure.STNE shares have surged 77.4% year to date. The Zacks Consensus Estimate for STNE's full-year 2025 earnings is pegged at $1.43 per share, up by 3.62% over the past 30 days, indicating an increase of 5.93% from the year-ago quarter's reported figure.TRVG shares have surged 95% year to date. The Zacks Consensus Estimate for TRVG's full-year 2025 earnings per share is pegged at 10 cents, unchanged over the past 30 days, indicating a rise of 11.11% from the year-ago quarter's reported figure.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Science Applications International Corporation (SAIC) : Free Stock Analysis Report
Paylocity Holding Corporation (PCTY) : Free Stock Analysis Report
Trivago N.V. ADS (TRVG) : Free Stock Analysis Report
StoneCo Ltd. (STNE) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
Relay Therapeutics (RLAY) Upgraded to Buy: What Does It Mean for the Stock?
Relay Therapeutics, Inc. (RLAY) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate. Since a changing earnings picture is a powerful factor influencing near-term stock price movements, the Zacks rating system is very useful for individual investors. They may find it difficult to make decisions based on rating upgrades by Wall Street analysts, as these are mostly driven by subjective factors that are hard to see and measure in real time. Therefore, the Zacks rating upgrade for Relay Therapeutics basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price. Most Powerful Force Impacting Stock Prices The change in a company's future earnings potential, as reflected in earnings estimate revisions, has proven to be strongly correlated with the near-term price movement of its stock. That's partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their bulk investment action then leads to price movement for the stock. For Relay Therapeutics, rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company's underlying business. And investors' appreciation of this improving business trend should push the stock higher. Harnessing the Power of Earnings Estimate Revisions Empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, so it could be truly rewarding if such revisions are tracked for making an investment decision. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions. The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> . Earnings Estimate Revisions for Relay Therapeutics For the fiscal year ending December 2025, this company is expected to earn -$1.73 per share, which is unchanged compared with the year-ago reported number. Analysts have been steadily raising their estimates for Relay Therapeutics. Over the past three months, the Zacks Consensus Estimate for the company has increased 6.6%. Bottom Line Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of "buy" and "sell" ratings for its entire universe of more than 4,000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a "Strong Buy" rating and the next 15% get a "Buy" rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term. You can learn more about the Zacks Rank here >>> The upgrade of Relay Therapeutics to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Relay Therapeutics, Inc. (RLAY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
21 hours ago
- Yahoo
Here's Why Accenture (ACN) is a Strong Value Stock
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike. Achieving those goals is made easier with the Zacks Style Scores, a unique set of guidelines that rates stocks based on popular investing methodologies, namely value, growth, and momentum. The Style Scores can help you narrow down which stocks are better for your portfolio and which ones can beat the market over the long-term. Why Investors Should Pay Attention to This Value Stock Value investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, and Price/Cash Flow, the Value Style Score identifies the most attractive and most discounted stocks. Accenture (ACN) Years of investment in digital, cloud and security strategy has helped Accenture evolve as a trusted and viable consulting services provider. It is currently one of the top consultancy firms of the world by revenues that increased 1.2% in fiscal 2024. ACN is a Zacks Rank #3 (Hold) stock, with a Value Style Score of B and VGM Score of A. Shares are currently trading at a forward P/E of 18.6X for the current fiscal year compared to the Computers - IT Services industry's P/E 17X. Additionally, ACN has a PEG Ratio of 2.2 and a Price/Cash Flow ratio of 15.4X. Value investors should also note ACN's Price/Sales ratio of 2.2X. Many value investors pay close attention to a company's earnings as well. For ACN, eight analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.19 to $12.88 per share for 2025. ACN boasts an average earnings surprise of 3%. ACN should be on investors' short list because of its impressive earnings and valuation fundamentals, a good Zacks Rank, and strong Value and VGM Style Scores. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Accenture PLC (ACN) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
Here's Why OneMain Holdings (OMF) is a Strong Value Stock
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike. Achieving those goals is made easier with the Zacks Style Scores, a unique set of guidelines that rates stocks based on popular investing methodologies, namely value, growth, and momentum. The Style Scores can help you narrow down which stocks are better for your portfolio and which ones can beat the market over the long-term. Why Investors Should Pay Attention to This Value Stock Value investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, and Price/Cash Flow, the Value Style Score identifies the most attractive and most discounted stocks. OneMain Holdings (OMF) Headquartered in Evansville, IN, OneMain Holdings Inc. (formerly known as Springleaf Holdings, Inc.) is a financial services company engaged in consumer finance and insurance businesses. In 2015, Springleaf acquired OneMain Financial from Citigroup and changed its name to the current one. OMF boasts a Value Style Score of A and VGM Score of A, and holds a Zacks Rank #3 (Hold) rating. Shares of OneMain Holdings are trading at a forward earnings multiple of 9.2X , as well as a PEG Ratio of 0.5, a Price/Cash Flow ratio of 8.1X, and a Price/Sales ratio of 1.3X. Value investors don't just pay attention to a company's valuation ratios; positive earnings play a crucial role, too. Eight analysts revised their earnings estimate upwards in the last 60 days for fiscal 2025. The Zacks Consensus Estimate has increased $0.16 to $6.34. OMF has an average earnings surprise of 9.3%. With strong valuation and earnings metrics, a good Zacks Rank, and top-tier Value and VGM Style Scores, investors should strongly think about adding OMF to their portfolios. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report OneMain Holdings, Inc. (OMF) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
